NCT06052033 Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection
| NCT ID | NCT06052033 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital of Wenzhou Medical University |
| Condition | HPV-Related Cervical Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-09-11 |
| Primary Completion | 2024-08-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2023-09-11 with a primary completion date of 2024-08-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Non-RCT clinical trial comparing 5-ALA photodynamic therapy and CO2 laser for persistent high-risk HPV-related low-grade cervical lesions.
Eligibility Criteria
Inclusion Criteria: 1. Aged 18-65 years old with a history of sexual activity. 2. Subclinical infected individuals who have been confirmed as HR-HPV positive (if there is the same positive type in the typing test) for more than 1 year using HPV typing test, HPV E6/E7 mRNA test, HPV DNA test, and cervical triple step diagnostic procedure (cytology colposcopy histopathology). 3. Patients diagnosed with LSIL by pathological examination of cervical biopsy under colposcopy with an interval of more than 1 year. 4. No fundamental diseases of important organs. 5. Agree to receive treatment and/or follow-up according to regulations and sign an informed consent form. 6. There has been no history of using other drugs related to HPV infection in the past 3 months. Exclusion Criteria: 1. HR-HPV persistent infection. 2. A total hysterectomy has been performed. 3. Concomitant endometrial cancer, ovarian cancer, and other reproductive tract tumors. 4. Complicated with abnormal heart, liver, and kidney functions, immune dysfunction, or immune system diseases such as systemic lupus erythematosus (SLE). 5. Using drugs such as immunosuppressants, antiviral agents, and glucocorticoids. 6. Pregnant and lactating women. 7. Acute reproductive tract inflammation. 8. Diabetes patients with uncontrolled blood sugar. 9. Patients who do not receive full treatment and follow-up. 10. Those who fail to sign the informed consent form.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06052033 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 65 Years, studying HPV-Related Cervical Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06052033 currently recruiting?
Yes, NCT06052033 is actively recruiting participants. Contact the research team at 627830566@qq.com for enrollment information.
Where is the NCT06052033 trial being conducted?
This trial is being conducted at Wenzhou, China.
Who is sponsoring the NCT06052033 clinical trial?
NCT06052033 is sponsored by First Affiliated Hospital of Wenzhou Medical University. The trial plans to enroll 40 participants.